215258-30-3Relevant academic research and scientific papers
A novel class of orally active non-peptide bradykinin B2 receptor antagonists. 2. Overcoming the species difference between guinea pig and man
Abe, Yoshito,Kayakiri, Hiroshi,Satoh, Shigeki,Inoue, Takayuki,Sawada, Yuki,Inamura, Noriaki,Asano, Masayuki,Hatori, Chie,Sawai, Hiroe,Oku, Teruo,Tanaka, Hirokazu
, p. 4053 - 4061 (2007/10/03)
Recently we reported the identification of a series of 8-[[3-(N- acylglycyl-N-methylamino)-2,6-dichlorobenzyl]oxy]-3-halo-2-methytimidazo[1,2- α]pyridines as the first orally active non-peptide bradykinin (BK)B2 receptor antagonists (1-3). Thes
BRADYKININ ANTAGONIST QUINOLINES
-
, (2008/06/13)
This invention relates to new heterocyclic compounds and pharmaceutically acceptable salts thereof. More particularly, this invention relates to new heterocyclic compounds and salts thereof which display bradykinin antagonist activity, to processes for preparing these compounds, to a pharmaceutical composition comprising these compounds, and to methods of using same in the prevention and/or the treatment of bradykinin-or bradykinin analogue-mediated diseases such as allergy, inflammation, autoimmune disease, shock, pain, or the like, in human beings or in animals.
IMIDAZO [1,2-A] PYRIDINES AND THEIR PHARMACEUTICAL USE
-
, (2008/06/13)
The invention relates to novel bradykinin antagonists of the formula: STR1 wherein R 1 is halogen,R 2 and R 3 are each hydrogen, lower alkyl, halo(lower)alkyl or acyl,R 4 is aryl having suitable substituent(s), or a heterocyclic group optionally having suitable substituent(s),Q is O or N--R 11, in which R 11 is hydrogen or acyl, andA is lower alkylene,and pharmaceutically acceptable salts thereof.
